Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 20, 2004 Ben McClure	Icahn Targets Mylan The billionaire's presence at the generic-drug maker Mylan could be bad news for management there, but good news for shareholders.
The Motley Fool October 29, 2004 Bill Mann	King, Knave, or Village Idiot? Troubled King Pharmaceuticals' latest accounting woes threaten to scuttle its merger with Mylan.
The Motley Fool February 8, 2005 Tom Taulli	Retro Raider Strikes Again Carl Icahn has been very busy lately -- and his most recent prey is cardboard packaging manufacturer Temple-Inland. The stock closed unchanged yesterday at $75.75. It had surged 16% when his interest in the stock became public.
The Motley Fool October 4, 2006 Brian Lawler	Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home.
The Motley Fool January 12, 2006 Rich Duprey	Will the SEC Trim the Hedges? As hedge funds are immersing themselves even more in mergers and acquisitions, a field that is fast approaching $1 trillion a year, it's not surprising that they will now also find themselves under closer scrutiny by regulators.
The Motley Fool March 23, 2005 Stephen D. Simpson	Kerr-McGee Gets the Message Will this deepwater driller, a historical underachiever, succeed in acting in shareholders' best interests?
BusinessWeek March 6, 2006 Ronald Grover	Carl Icahn: Still An Improbable Robin Hood Carl Icahn is out to recast himself as the hedge fund investor's champion. That image has its critics.
The Motley Fool July 22, 2011 Evan Niu	Clorox to Icahn: "It's Not You, It's Me" Clorox announces that its board has unanimously rejected Icahn's unsolicited bid to acquire the company.
The Motley Fool January 12, 2006 Stephen D. Simpson	Forest Keeps Reloading An agreement with Mylan Labs gives Forest access to a drug that could be launched in 2006. Investors, take note.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool October 14, 2011 Travis Hoium	Navistar International Shares Popped: What You Need to Know Shares of Navistar International drove as much as 16% higher today before dropping to a more modest gain of 8% mid-day.
The Motley Fool March 23, 2010 Brian Orelli	Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next?
The Motley Fool May 31, 2005 Tom Taulli	The Icahn Effect Carl Icahn has spread fear throughout corporate boardrooms. Now hedge fund Relational Investors looks like an Icahn wannabe.
National Real Estate Investor December 4, 2002 Parke Chapman	Investor now holds 6.9% stake in Insignia Carl Icahn now holds a 6.9% stake in real estate operator Insignia Financial Group Inc.
The Motley Fool October 25, 2006 Brian Lawler	Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn.
The Motley Fool September 29, 2006 Brian Lawler	ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree.
The Motley Fool September 15, 2008 Brian Orelli	Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company.
The Motley Fool September 21, 2006 Brian Lawler	ImClone's Board Shakeup A new face in the boardroom heralds change for the troubled company. Shareholders yesterday elected notorious corporate raider Carl Icahn to the company's board of directors.
The Motley Fool June 22, 2011	Here's What Carl Icahn Bought and Sold Last Quarter A look under the hood at what Carl Icahn was up to in the first three months of 2011.
The Motley Fool April 15, 2005 Tom Taulli	Carl Icahn Strikes Again Energy and inorganic-chemical company Kerr-McGee and investor Icahn make peace. The market's happy, and Icahn's war chest just gets bigger.
The Motley Fool January 29, 2008 Brian Lawler	Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec.
The Motley Fool August 1, 2008 Brian Lawler	Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal?
The Motley Fool October 12, 2005 W.D. Crotty	Icahn's Case for Time Warner Carl Icahn issues an open letter to shareholders pushing for change on the company's board. Investors should realize, though, that just because Icahn is around, that doesn't mean their shares will automatically go up.
The Motley Fool April 6, 2011	Here's What Icahn Capital Bought and Sold Last Quarter Carl Icahn is CEO of Icahn Capital, which is a privately owned hedge fund sponsor that invests in small- and medium-sized companies having undervalued share prices. Let's take a look at their recent moves.
The Motley Fool November 18, 2008 Brian Orelli	Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere.
InternetNews March 24, 2008 Judy Mottl	Icahn Challenges Motorola on Handheld Strategy Motorola stockholder and longtime critic Carl Icahn is seeking answers about the company's floundering performance, filing a lawsuit today seeking documents related to Moto's beleaguered mobile device division.
The Motley Fool February 7, 2007 Brian Lawler	Mylan Adjusts to the Matrix The drugmaker got a bump from a new generic and settles in with its Matrix acquisition. Investors, take note.
The Motley Fool September 24, 2008 Brian Lawler	Bristol-Myers Puts Icahn and ImClone to the Test Despite trying to project different intentions last week, pharma giant Bristol-Myers Squibb raised its bid for ImClone Systems.
The Motley Fool May 14, 2007 Brian Lawler	Mylan Goes on a Drug Binge The generic drugmaker makes a hefty acquisition, but it's hard to say at this point how good of a deal this is for shareholders.
The Motley Fool July 8, 2008 Rick Aristotle Munarriz	Doesn't Yahoo! Get a Say? Billionaire investor Carl Icahn and Microsoft insist that only a new boardroom -- ideally populated by the slate of directors that Icahn is proposing -- will lead Microsoft to reopen acquisition talks with Yahoo!.
The Motley Fool December 21, 2004 Rich Smith	Norilsk Wags the Dog Does the Gold Fields Russian shareholder call the shots in this troubled South African goldmine merger?
The Motley Fool July 23, 2008 Rick Aristotle Munarriz	Icahn's Spotty Track Record Carl Icahn and Yahoo! have made nice, in advance of next week's meeting, but will the peace last? Or is the current calm just the eye of the hurricane?
The Motley Fool May 12, 2008 Brian Orelli	Merging Mylan Meanders Through 2008 In the larger-is-better world of generic-drug makers, it's kind of surprising that investors haven't yet gotten behind the Mylan/Merck KGaA deal.
The Motley Fool October 30, 2009 Brian Orelli	It's Not As Frightening As It First Appears Dig a little, and you'll see that generic-drug maker Mylan is far from a copycat of its struggling branded-drug-making counterparts.
The Motley Fool December 15, 2010 Toby Shute	This Corporate Raider Hasn't Lost His Touch Has Carl Icahn outsmarted Blackstone with his bid for utility company Dynegy? The tentative answer today appears to be yes.
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
The Motley Fool May 16, 2007 Rich Duprey	Mylan's Costly Bid to Capture the Flag Its winning bid for a German Merck unit might be why it's falling behind in the generics game. Investors, take note.
BusinessWeek March 5, 2007 Ronald Grover	Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola.
The Motley Fool July 31, 2009 Brian Orelli	Two Pictures of a Drug Company Who should we believe? The FDA? Mylan's earnings report?
The Motley Fool August 5, 2008 Brian Lawler	An ImClone Deal Will Get Done Despite his tough talk, Icahn will likely complete a buyout of ImClone.
The Motley Fool July 27, 2009 Brian Orelli	Mylan Ruins It for Everyone If customers begin to mistrust generic drugs from Mylan or whoever -- fearing that the companies are putting profits above safety -- all generic-drug companies will be hurt.
The Motley Fool June 11, 2008 Brian Lawler	He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head.
The Motley Fool February 8, 2006 Rick Aristotle Munarriz	Time Warner's Splitting Headache Carl Icahn's investment banker suggests Time Warner break up into four pieces. But the company is doing its part to make investors know that it's not asleep at the wheel. With every quarterly improvement, Icahn's voice is likely to grow that much quieter.
The Motley Fool November 30, 2005 Rick Aristotle Munarriz	I Think Icahn, Time Warner Despite the market's interest in Time Warner's online operations, billionaire investor Carl Icahn still believes that more can be done to improve shareholder value.
The Motley Fool June 4, 2009 Brian Orelli	Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price.
The Motley Fool June 10, 2010 Brian Orelli	Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday.
The Motley Fool February 17, 2006 Rick Aristotle Munarriz	A Time for Peace Carl Icahn appears to have come to a truce with Time Warner over his breakup plans. However, a significant show of shareholders siding with Icahn's nominees may also force Time Warner to take a harder look at why it can't seem to get its stock out of the high teens.
The Motley Fool May 12, 2005 Rick Aristotle Munarriz	Icahn's Blockbuster Move Billionaire investor Carl Icahn wins a spot on the Blockbuster board, but that's only the beginning. Blockbuster has really been trying the patience of its shareholders lately.
The Motley Fool August 12, 2005 Tom Taulli	Big Game Hunter As usual, Carl Icahn has a good sense of shifts in Corporate America. By taking a position on Time Warner, he's certainly going to be heard. And divvying up some of the assets may produce higher returns for shareholders as well.
The Motley Fool September 1, 2009 Rick Aristotle Munarriz	Icahn Handles the Truth at Yahoo! Carl Icahn has sold shares of struggling online giant Yahoo! in each of the past three trading days, enough to take his stake below 5%.